April 2013

BOSTON, MA – HEMARINA, the French based Biotechnology Company, today announced its establishment in Boston, Massachusetts USA thru the incorporation of Hemarina Inc. on March 15th, 2013.

The new affiliate will be in charge of North and South America and will allow HEMARINA to deploy its global strategy more efficiently, and will be the corporate link between its headquarters located in Morlaix, France to facilitate its partnerships in the Americas. Seven years after its creation, HEMARINA has decided to accelerate its developments and anticipates the registration of its product HEMO2Life® which is an additive to organ preservation solutions to enhance, and improve organ quality and preservation duration and conditions in the transplantation field. As one the world’s leading Life Sciences hubs, Boston and Cambridge, has a most flourishing and attractive environment, and therefore is a natural choice for a biotechnology company like HEMARINA.

Dr. Franck Zal, Chief Executive Officer and Scientific Executive Officer, HEMARINA commented: “The U.S. pharma and biotech markets tend to be early technology adopters, and Boston is an ideal location for Hemarina Inc. to benefit from this rich innovation ecosystem from a culture and networks perspectives. Furthermore, the new affiliate office is expected to facilitate the administrative and operational processes required for HEMARINA with its scientific and commercial partners in the United States including ongoing collaborations such as with the Naval Medical Research Center (NMRC) and Naval Medical Research Unit of San Antonio (NAMRU-SA).” The affiliate has been organized in collaboration with the law firm of Morse, Barnes-Brown & Pendleton, and ITRA Global|The Stevens Group. Morse, Barnes-Brown & Pendleton will continue to act as legal counsel for Hemarina Inc. in its operations. The offices of Hemarina Inc. will be located in Ten Post Office Square, 8th Floor Boston, MA 02109.


HEMARINA is a biotechnology start-up based in Morlaix, France; developing innovative solutions for patients and healthcare industry based on its universal oxygen carriers portfolio and pipeline products. HEMARINA has four core business programs, all of which are patented breakthrough innovations: organ transplantation and tissue conservation, blood substitutes, infections and wound healing, and bio-production. HEMARINA’s core assets and know-how are based on marine molecules, and its corporate culture, policy and social responsibility are based on a focus on large unmet medical needs, a public health issues-solving mindset, excellence in science and processes, and nature conservation and environment friendly approaches and attitud

About Morse, Barnes-Brown & Pendleton:

Morse, Barnes-Brown & Pendleton focuses exclusively on the core legal services that businesses need to succeed. The firm is built on a unique business model that provides its clients with access to highly experienced counsel in the areas of corporate and corporate finance law; intellectual property; licensing and strategic alliances; employment and immigration; and tax planning and defense. While it enjoys a reputation for special competency in life sciences and other technology ventures, it represents clients in all industries and of all sizes – from startups to Fortune 1000 companies.

About ITRA Global | The Stevens Group:

The Stevens Group was founded in 1980 to provide commercial real estate services to corporate clients, assisting them in the leasing, acquisition and disposition of commercial real estate. The Stevens Group’s mission is to provide its clients with the most complete, unbiased real estate advice and the most efficient systems in business real estate, combining international reach and local knowledge to obtain the best possible space at the best possible terms.